Dr Fiona Mclaughlin

Biography

 Dr Fiona McLaughlin is the Head of Research and Development for the Heidelberg based oncology biotechnology company Elara Pharmaceuticals GmbH, responsible for progression of the drug development pipeline and licensing/collaboration activities. Prior to joining Elara, Dr McLaughlin was Director of Research and a member of the Senior Management Team at the UK based Antisoma Research Ltd from 2007-2010. Following Antisoma's acquisition of Boston-based Xanthus Pharmaceuticals Inc, she became VP Translational Research for the expanded company and built up an innovative portfolio of in-licensed early stage oncology assets. Prior to joining Antisoma, she has held the posts of Oncology Development Specialist and Head of Pre-Clinical development for the specialty pharmaceuticals company BTG in London, combining virtual drug development and in-licensing to expand and progress the drug development portfolio. From 2001-2004 Dr McLaughlin was Head of Biology for the Oxford based oncology company Prolifix Ltd which was later acquired by Topotarget A/S. Throughout this time she was primarily responsible for the research and non-clinical development activities that led to the clinical development of the HDAC inhibitor Belinostat. Dr McLaughlin gained her PhD from the Haematology Department at Cambridge University and carried out post-doctoral research at GlaxoSmithKline in the UK, where she subsequently held several research posts in vascular diseases, inflammation and steroid induced osteoporosis. In addition to her current post at Elara Pharmaceuticals, Dr McLaughlin is also an independent consultant to the pharmaceutical industry and is a fully elected Fellow of the Society of Biology.

Research Interest

 Resaerch interest on HEmatology , Biology